Overcome Targeted Alpha Therapy Challenges for Clinical Translation
Earn a Certificate of Live Attendance
AI Webinar Explorer available after event
About this webinar
Targeted alpha therapies are emerging as a promising area of radiopharmaceutical development, delivering high-potency, short-range radiation designed to target cancer cells while limiting damage to surrounding healthy tissue. As pipelines expand beyond beta-emitting therapies, radionuclides including actinium-225 (Ac-225), lead-212 (Pb-212) and astatine-211 (At-211) are attracting growing interest. This webinar explores the scientific and technical considerations shaping the development and clinical translation of targeted alpha therapy.
Despite their therapeutic potential, advancing targeted alpha therapies toward clinical applications requires overcoming several scientific and technical challenges that can influence overall development success. Key considerations include vector selection, radiochemistry, chelation and stability, as well as the complexities of dosimetry, biodistribution and toxicity. Additionally, daughter radionuclide redistribution, isotope availability and production scalability introduce further challenges that can affect therapeutic safety, efficacy and clinical readiness.
The featured speaker will explore the evolving targeted alpha therapy landscape, from key radionuclides and radiochemistry strategies to dosimetry, toxicity, isotope supply and translation. Attendees will gain a practical perspective on the scientific challenges that must be addressed to advance alpha-emitting radiopharmaceuticals toward the clinic.
Register for this webinar to learn about the key challenges in targeted alpha therapy development and the considerations necessary to support successful clinical translation.
Who should attend
- Radiopharmaceutical and RLT Developers
- R&D and Translational Scientists
- Radiochemists and Medicinal Chemists
- Preclinical and In Vivo Researchers
- Imaging and Nuclear Medicine Scientists
- Dosimetry and Medical Physics Specialists
- Oncology and Clinical Development teams
What you will learn
- How alpha therapies differ from beta-emitting approaches
- Key considerations for Ac-225, Pb-212 and At-211
- Radiochemistry, chelation and stability challenges
- Dosimetry, biodistribution and clinical translation
- Daughter redistribution and toxicity considerations
- Production, supply and scalability challenges
Featured Speakers
Julian Goggi, PhD
Julian Goggi, PhD, is a Translational Scientist with over 20 years of experience in radiopharmaceutical research and development, specializing in the development of radioligand therapies and diagnostic radiopharmaceuticals across oncology, neurology and metabolic diseases. He has held senior roles in Europe and Asia, managing multidisciplinary teams and collaborations and has authored over 60 peer-reviewed publications. He is currently serving as Director and Scientific Lead at Perceptive Inc, overseeing IND-enabling studies for radioligand therapy development.
Partner for this event
Perceptive Discovery
Perceptive Discovery bridges the gap between preclinical insights and early clinical success, providing the expertise and high-quality data needed to advance innovation with confidence. With deep expertise in advanced imaging, radiochemistry, and translational science, we specialize in supporting drug development programs across CNS, oncology, and radioligand therapy. Our integrated approach combines rigorous scientific analysis, state-of-the-art imaging platforms, and multidisciplinary expertise to deliver data that drives smarter decisions, reduces risk, and accelerates timelines from preclinical to first-in-human studies.